252 related articles for article (PubMed ID: 30402608)
1. Epidemiology of cutaneous adverse drug reactions.
Mockenhaupt M
Allergol Select; 2017; 1(1):96-108. PubMed ID: 30402608
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of cutaneous adverse drug reactions.
Mockenhaupt M
Chem Immunol Allergy; 2012; 97():1-17. PubMed ID: 22613850
[TBL] [Abstract][Full Text] [Related]
3. Stevens-johnson Syndrome and Toxic Epidermal Necrolysis: An Overview of Diagnosis, Therapy Options and Prognosis of Patients.
Garg VK; Buttar HS; Bhat SA; Ainur N; Priya T; Kashyap D; Tuli HS
Recent Adv Inflamm Allergy Drug Discov; 2023; 17(2):110-120. PubMed ID: 37605396
[TBL] [Abstract][Full Text] [Related]
4. Association between human leukocyte antigens and cutaneous adverse drug reactions to antiepileptics and antibiotics in the Iranian population.
Mortazavi H; Rostami A; Firooz A; Esmaili N; Ghiasi M; Lajevardi V; Amirzargar AA; Sheykhi I; Khamesipour A; Akhdar M
Dermatol Ther; 2022 May; 35(5):e15393. PubMed ID: 35187767
[TBL] [Abstract][Full Text] [Related]
5. Skin tests in the work-up of cutaneous adverse drug reactions: A review and update.
Barbaud A; Castagna J; Soria A
Contact Dermatitis; 2022 May; 86(5):344-356. PubMed ID: 35122269
[TBL] [Abstract][Full Text] [Related]
6. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Lerch M; Mainetti C; Terziroli Beretta-Piccoli B; Harr T
Clin Rev Allergy Immunol; 2018 Feb; 54(1):147-176. PubMed ID: 29188475
[TBL] [Abstract][Full Text] [Related]
7. Toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Orphanet J Rare Dis; 2010 Dec; 5():39. PubMed ID: 21162721
[TBL] [Abstract][Full Text] [Related]
8. HLA-B (*) 58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand.
Sukasem C; Jantararoungtong T; Kuntawong P; Puangpetch A; Koomdee N; Satapornpong P; Supapsophon P; Klaewsongkram J; Rerkpattanapipat T
Front Pharmacol; 2016; 7():186. PubMed ID: 27486401
[TBL] [Abstract][Full Text] [Related]
9. [Severe skin reactions due to new medications].
Mockenhaupt M; Paulmann M
Hautarzt; 2018 Apr; 69(4):278-289. PubMed ID: 29568997
[TBL] [Abstract][Full Text] [Related]
10. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
[TBL] [Abstract][Full Text] [Related]
11. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM
Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
[TBL] [Abstract][Full Text] [Related]
12. A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs).
Singh GK; Mitra B; Arora S; Akhoon N; Verma R; Sharma P; Mitra D
Int J Dermatol; 2021 May; 60(5):579-588. PubMed ID: 33454956
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
[TBL] [Abstract][Full Text] [Related]
14. Dermoscopic Aspects of Cutaneous Adverse Drug Reactions.
Rossi G; da Silva Cartell A; Marchiori Bakos R
Dermatol Pract Concept; 2021 Jan; 11(1):e2021136. PubMed ID: 33614215
[TBL] [Abstract][Full Text] [Related]
15. Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators.
Chu MT; Chang WC; Pao SC; Hung SI
Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672685
[TBL] [Abstract][Full Text] [Related]
16. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
[TBL] [Abstract][Full Text] [Related]
17. Adverse cutaneous drug eruptions: current understanding.
Hoetzenecker W; Nägeli M; Mehra ET; Jensen AN; Saulite I; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
Semin Immunopathol; 2016 Jan; 38(1):75-86. PubMed ID: 26553194
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous adverse drug reactions.
Bettuzzi T; Sanchez-Pena P; Lebrun-Vignes B
Therapie; 2024; 79(2):239-270. PubMed ID: 37980248
[TBL] [Abstract][Full Text] [Related]
19. Paracetamol (Acetaminophen)-associated SJS, TEN, AGEP, and DRESS Syndromes - A Narrative Review.
Pakkir Maideen NM; Barakat IR; Jumale AH
Curr Drug Saf; 2024; 19(2):218-223. PubMed ID: 37151075
[TBL] [Abstract][Full Text] [Related]
20. [Cutaneous adverse drug reactions].
Lebrun-Vignes B; Valeyrie-Allanore L
Rev Med Interne; 2015 Apr; 36(4):256-70. PubMed ID: 25458866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
